Hospital-Treated Infections | Pharmacor | G7 | 2014
Last Updated 15 December 2014
Hospital-treated infections (HTIs) constitute a high-value segment of the antibacterial market owing to their severity, which drives the use of potent and branded antibiotics, compared with infections that can be treated solely in the outpatient setting. In addition, common pathogens and antimicrobial resistance in HTIs often necessitate the administration of high-cost, fast-acting intravenous antibiotics with activity against drug-resistant pathogens. However, because this market is already well served with many generically available agents from a range of drug classes, new and emerging therapies will find firm competition from established standard-of-care therapies. In addition, greater implementation of antimicrobial stewardship programs and cost-containment measures will likely further restrict the use of newer agents to later lines of therapy to reduce the risk of drug resistance development and minimize overall healthcare expenditures. Despite these challenges, the expanding population of at-risk patients and the growing rates of multidrug resistance, especially among gram-negative pathogens (GNPs), will provide commercial opportunities for novel agents. With many new therapies launching within the forecast period as well as entry of generic versions of key HTI brands, marketers will need to highlight efficacy and pharmacoeconomic benefits in order to succeed in the increasingly competitive HTI market.
